Amgen Inc.'s value-based pricing strategy for its PCSK9 inhibitor Repatha is continuing to win preferred status on payer formularies, with the latest win being sole position on the commercial formulary offered by CVS Health Corp.'s pharmacy benefit manager CVS/caremark.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?